Compound class:
Synthetic organic
Comment: TXA709 is an orally bioavailable prodrug of TXA707 (PubChem: 90135655), a benzamide antibacterial compound that inhibits the essential and conserved prokaryotic cell division protein FtsZ [3]. TXA709 is under clinical development, as a combination therapy with synergistic drug partners, for infections caused by methicillin-resistant Staphylococcus aureus (MRSA) [1-2].
|
|
No information available. |
Summary of Clinical Use |
TAXIS Pharmaceuticals report that TXA709 has completed a first-in-human Phase 1 clinical trial with no serious adverse events recorded [4]. We have been unable to find the registration for this clinical trial. In September 2016, TXA709 was granted Qualified Infectious Disease Product (QIDP) designation by the US FDA. |